for the advantage of the reader how personality and timeliness of ideas have been major forces in the growth of our understanding of the "Wisdom of the Body." Especially to be recommended to students interested in tracing the background of modern concepts in neurophysiology are the essays by Professor Horace W. Magoun on "The development of ideas relating the mind with the brain," and Professor John F. Fulton "Historical backgrounds of neurophysiology." In the latter Dr. Fulton draws effectively on his associations with Sherrington and Pavlov to fix their respective roles in the growth of our understanding of behavior. Dr. Chandler Brooks, one of the editors of the volume, has contributed an excellent review of the stages in "The discovery of the function of chemical mediators in transmission of excitation and inhibition to effector tissues." For the student this review should have especial interest, for here he will see the fingerpointings to the truth a full thirty years before men's minds were prepared to accept an explanation that challenged naught but tradition.
This selection of specific essays from the group betrays the reviewer's special interests. They are all of high quality and each one certain to reward the reader. November 20-22, 1958 . It presents reports ranging from structureactivity relationships of new series of MAO inhibitors to the clinical evaluation of these compounds; it should, therefore, have an appeal for a wide variety of workers in this area of research, from laboratory investigators to psychiatrists.
Most of the investigators at the conference agreed that the clinical properties of these compounds are interesting, promising, and worthy of further work. It would appear from their reports that these drugs have some potential value in the following clinical conditions. 1. Psychiatric disorders. This is probably the most important area of their application. Generally, chronic schizophrenics who are apathetic or depressed respond better than those with agitated depression or those classified as acute schizophrenics. In this latter group, as many as 75 per cent may be made worse by these agents. These are the findings of Bailey et al. who also report success in refractory patients by using a combination of an MAO inhibitor and a tranquilizer. A group from Boston (Alexander and Berkely) illustrated the important point that careful selection of patients for therapy with iproniazid can lead to a much higher percentage of success than poor selection. They reported a recovery rate of 88 per cent in a group classified as psychesthenic-anhedonic in contrast to only 26 per cent recovery among those exhibiting classical depressive reactions. A number of other papers on the efficacy of these drugs in psychiatric disorders have the same positive and optimistic tone, but it seems safe to say that their ultimate place in psychiatry must await many more definitive studies. Voelkel of Berlin (Waldhaus Mental Hospital) made an interesting point when he generalized that the action of the hydrazides occurs in two phases: activity is affected first, followed by alteration of mood. Possibly the greatest single drawback to these drugs, apart from their toxicity, is their relatively slow onset of action. There is a good likelihood that more effective agents in this category will be introduced in the future.
2. Angina pectoris and coronary disease. Cesarman of the National Institute of Cardiology of Mexico, who first observed the beneficial action of iproniazid in angina pectoris, has indicated that this application was a clear case of serendipity; and today even hints as to the mechanism of this action are few and obscure. Nevertheless, all investigators at this conference were in agreement that good results may be expected from iproniazid and, presumably, from related compounds. There was also general agreement on the relief of pain and the mental changes produced by these compounds, such as euphoria, excitement, and loss of perception of the angina. On the other hand, there was disagreement about whether iproniazid can correct ECG-abnormalities and change the response to the Master exercise test. One important point which emerged from these reports is that one obtains no therapeutic results without attendant side-effects.
3. Diseases of the gastro-intestinal tract. In a number of conditions like colitis, hepatitis, anorexia nervosa, etc., in which patients suffer from lack of appetite and malnutrition, Weiss and co-workers reported improvement in appetite and sense of well-being after long-term therapy with iproniazid. Their data strongly suggest that the appetite-improvement is a direct result of a significant reduction in blood glucose.
4. Rheumatoid arthritis. An interesting paper by Scherbel and Harrison (Cleveland Clinic) demonstrated that iproniazid may have a place in the treatment of retarded psychomotor activity, emotional lability, and other CNS manifestations occurring in patients with rheumatoid arthritis and related diseases. It was made clear that the drug had no effect on the objective signs, nor did it alter the clinical laboratory data. But there was improvement in motility and in the subjective symptoms of these patients.
It becomes apparent from the clinical papers presented here and from those directly reporting toxicity that these drugs have a toxic potential of considerable proportions. The toxicity of iproniazid ranges from annoying side-effects like dizziness, urinary retention, and impotence to serious and sometimes fatal hepatocellular changes. In general, it is felt that serious toxicity can be avoided by keeping the dosage of iproniazid under 150 mg. daily.
While there is no question that these drugs influence the metabolism of amines within the organism, papers dealing with mechanism of action failed to present rigorous evidence to support the view that inhibition of MAO can account for all of the effects observed with these drugs. In the mind of the reviewer there is little reason to doubt that other mechanisms are also involved.
